Executive Vice President and Chief Commercial Officer
Andrew Partridge serves as executive vice president and chief commercial officer. Mr. Partridge has more than 20 years of global pharmaceutical sales and marketing experience leading more than 20 commercial launches across multiple indications, including oncology, hematology and rare diseases.
Prior to joining Turning Point Therapeutics, Mr. Partridge was both chief operating officer and chief commercial officer of Centrexion Therapeutics, a privately held biotech. He was previously with Vertex Pharmaceuticals for 5 years, most recently as senior vice president and head of North American commercial operations where he built the team to successfully launch multiple cystic fibrosis therapies and new indications. Mr. Partridge had overall responsibility at Vertex across the U.S. and Canada for marketing, sales, market access and patient services and led the cross-functional North American leadership team that included medical affairs, finance, legal and human resources. In the preceding 20 years, he served in sales and marketing roles of increasing responsibility with Schering-Plough, Roche and Amgen. At Amgen, he held senior marketing and sales roles for oncology and hematology therapeutics, including strategic planning and operations of the $5 billion oncology business unit, and therapeutic area head for oncology in global strategic marketing. His global experience also includes marketing and sales management roles based in the U.K. at Roche and Schering-Plough focused on oncology and hematology. He earned a Higher National Diploma in Medical Laboratory Sciences from Birmingham City University in the U.K.